Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis

Jul 10, 2020
|
staff reporter

NEW YORK – Women carrying pathogenic germline BRCA1/2 variants who develop breast cancer appear to fare better if their germline risk variants were uncovered prior to their cancer diagnosis, even if they do not undergo preventative procedures such as risk-reduction surgery, according to new research from Israel.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Cancer

  1. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  2. Guardant Health Colorectal Cancer Early-Detection Test Progresses Despite Pandemic Challenges

    Premium

  3. Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

  4. Rakuten Medical Sues Illumina Over Trademark Dispute

  5. Computational Tool Analyzes Noncoding Mutations to Classify Cancer Subtypes

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.